Authors: Cecilia L. Moore, Anna Turkova , Hilda Mujuru , Adeodata Kekitiinwa, Abbas Lugemwa, Cissy M. Kityo, Linda N. Barlow-Mosha, et al, ODYSSEY trial team
Published in: BMC Infectious Diseases
Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) is highly effective and well-tolerated in adults and is rapidly being adopted globally. We describe the design of the ODYSSEY trial which evaluates the efficacy and safety of DTG-based ART compared with standard-of-care in children and adolescents.
Treat early, suppress fast!
In a new paper just published online in Journal of AIDS, EPIICAL researchers investigated the association between the timing of antiretroviral therapy (ART) initiation and time-to suppression among HIV-infected infants who initiated ART within the first 28 days of life.
The study showed as children treated within 7 days of life have a faster time to viral suppression, which may result in a favorable impact on the viral reservoir.